Postavke privatnosti

Latest research and technological advances in kidney cancer treatment: personalized therapies yield better results and longer life for patients

The development of new therapies, such as immunotherapy and targeted therapy, has significantly improved kidney cancer treatment. Personalized approaches and technological advances allow patients to achieve better outcomes and a higher quality of life, even in advanced stages of the disease

Latest research and technological advances in kidney cancer treatment: personalized therapies yield better results and longer life for patients
Photo by: Domagoj Skledar/ arhiva (vlastita)

NCI-funded researchers have made significant progress in understanding how to detect and treat kidney cancer. Recent studies show that new therapies, such as targeted therapy and immunotherapy, have significantly improved patient outcomes, particularly for those with advanced forms of the disease.

Advances in early detection of kidney cancer
Liquid biopsies, which involve analyzing DNA released by kidney tumors, represent a promising tool for the early detection of small kidney tumors. Although the results are promising, further research is needed to confirm the accuracy of these tests and enable their broader application in clinical practice.

Genetic testing and kidney cancer risk
About 5% to 8% of kidney cancers are caused by inherited genetic changes. Genetic testing now allows for the identification of these changes, helping with personalized monitoring of kidney health and potential disease prevention in high-risk individuals.

Targeted therapies for advanced kidney cancer
The most common type of kidney cancer, clear cell carcinoma, is often caused by changes in the VHL gene. Targeted therapies that inhibit specific pathways within these cells, such as the drug belzutifan, have shown significant improvement in patients with this type of cancer. This drug, which blocks the HIF-2α protein, has been approved for treating advanced clear cell kidney cancer and has demonstrated durable results in controlling the disease.

Rare types of kidney cancer and innovative approaches
For patients with papillary renal cell carcinoma, which accounts for about 15% of kidney cancer cases, new combination therapies such as cabozantinib and atezolizumab immunotherapy show significant potential. Studies indicate that such combinations may extend the time without disease progression and improve overall patient outcomes.

Immunotherapy as a key strategy in the fight against kidney cancer
Immunotherapy has become a central focus in treating kidney cancer, especially for patients with advanced-stage disease. Combinations of immunotherapeutic drugs, such as ipilimumab and nivolumab, show durable responses in patients, making this therapy a standard of care for certain patient groups.

New radiation methods and treatments for metastatic cancer
Recent research shows that stereotactic ablative radiation therapy (SABR), which uses targeted radiation beams to target tumors, can control metastatic kidney cancer and reduce the need for systemic therapy in patients with oligometastases. This method, which minimizes damage to surrounding tissues, could become a standard of care for patients with this form of the disease.

NCI-supported research programs
Numerous NCI programs support basic and clinical research in the field of kidney cancer. These programs, including specialized programs of excellence (SPOREs) and the National Clinical Trials Network (NCTN), ensure the effective translation of scientific discoveries into clinical practice, facilitating progress in treatment and long-term patient survival.

Source: National Cancer Institute US

Find accommodation nearby

Creation time: 30 August, 2024

Science & tech desk

Our Science and Technology Editorial Desk was born from a long-standing passion for exploring, interpreting, and bringing complex topics closer to everyday readers. It is written by employees and volunteers who have followed the development of science and technological innovation for decades, from laboratory discoveries to solutions that change daily life. Although we write in the plural, every article is authored by a real person with extensive editorial and journalistic experience, and deep respect for facts and verifiable information.

Our editorial team bases its work on the belief that science is strongest when it is accessible to everyone. That is why we strive for clarity, precision, and readability, without oversimplifying in a way that would compromise the quality of the content. We often spend hours studying research papers, technical documents, and expert sources in order to present each topic in a way that will interest rather than burden the reader. In every article, we aim to connect scientific insights with real life, showing how ideas from research centres, universities, and technology labs shape the world around us.

Our long experience in journalism allows us to recognize what is truly important for the reader, whether it is progress in artificial intelligence, medical breakthroughs, energy solutions, space missions, or devices that enter our everyday lives before we even imagine their possibilities. Our view of technology is not purely technical; we are also interested in the human stories behind major advances – researchers who spend years completing projects, engineers who turn ideas into functional systems, and visionaries who push the boundaries of what is possible.

A strong sense of responsibility guides our work as well. We want readers to trust the information we provide, so we verify sources, compare data, and avoid rushing to publish when something is not fully clear. Trust is built more slowly than news is written, but we believe that only such journalism has lasting value.

To us, technology is more than devices, and science is more than theory. These are fields that drive progress, shape society, and create new opportunities for everyone who wants to understand how the world works today and where it is heading tomorrow. That is why we approach every topic with seriousness but also with curiosity, because curiosity opens the door to the best stories.

Our mission is to bring readers closer to a world that is changing faster than ever before, with the conviction that quality journalism can be a bridge between experts, innovators, and all those who want to understand what happens behind the headlines. In this we see our true task: to transform the complex into the understandable, the distant into the familiar, and the unknown into the inspiring.

NOTE FOR OUR READERS
Karlobag.eu provides news, analyses and information on global events and topics of interest to readers worldwide. All published information is for informational purposes only.
We emphasize that we are not experts in scientific, medical, financial or legal fields. Therefore, before making any decisions based on the information from our portal, we recommend that you consult with qualified experts.
Karlobag.eu may contain links to external third-party sites, including affiliate links and sponsored content. If you purchase a product or service through these links, we may earn a commission. We have no control over the content or policies of these sites and assume no responsibility for their accuracy, availability or any transactions conducted through them.
If we publish information about events or ticket sales, please note that we do not sell tickets either directly or via intermediaries. Our portal solely informs readers about events and purchasing opportunities through external sales platforms. We connect readers with partners offering ticket sales services, but do not guarantee their availability, prices or purchase conditions. All ticket information is obtained from third parties and may be subject to change without prior notice. We recommend that you thoroughly check the sales conditions with the selected partner before any purchase, as the Karlobag.eu portal does not assume responsibility for transactions or ticket sale conditions.
All information on our portal is subject to change without prior notice. By using this portal, you agree to read the content at your own risk.